Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 8, 2013, Pages 665-670

  Levy, Finn Olav ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC GMP; NATRIURETIC PEPTIDE TYPE C; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; SEROTONIN RECEPTOR; SEROTONIN 4 RECEPTOR;

ACUTE HEART FAILURE; HEART ATRIUM; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE; HUMAN; INOTROPISM; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; HEART; HEART CONTRACTION; PHYSIOLOGY;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CYCLIC AMP; CYCLIC GMP; HEART; HUMANS; MYOCARDIAL CONTRACTION; PHOSPHORIC DIESTER HYDROLASES; RECEPTORS, SEROTONIN, 5-HT4; SIGNAL TRANSDUCTION;

EID: 84880287290     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0874-z     Document Type: Review

References (68)

1. 4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles. Br J Pharmacol 155:1005-1014
2. 2- adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle. Br J Pharmacol 162:54-71
3. 4-elicited positive inotropic response in failing rat cardiac ventricle. Naunyn-Schmiedeberg's Arch Pharmacol 384:543-553
4. 1-AR-induced positive inotropic response in heart is dependent on myosin light chain phosphorylation. Am J Physiol Heart Circ Physiol 283:H1471-H1480
5. 4 receptor antagonist in heart failure. Br J Pharmacol 150:143-152
6. 4 mRNA in heart failure. Naunyn-Schmiedeberg's Arch Pharmacol 370:157-166
7. 4 receptor is functional in late foetal development and is reactivated in heart failure. PLoS One 7:e45489
8. Brunton LL, Hayes JS, Mayer SE (1981) Functional compartmentation of cyclic AMP and protein kinase in heart. Adv Cyclic Nucleotide Res 14:391-397
9. Butcher RW, Sutherland EW (1962) Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J Biol Chem 237:1244-1250
10. 1-adrenoceptors in human atrial myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 374:249-253
11. 2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. Br J Pharmacol 156:62-83
12. CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13
13. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F III, DeMets DL, White BG (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339:1810-1816
14. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343:246-253
15. Corbin JD, Sugden PH, Lincoln TM, Keely SL (1977) Compartmentalization of adenosine 3′:5′-monophosphate and adenosine 3′:5′- monophosphate-dependent protein kinase in heart tissue. J Biol Chem 252:3854-3861
16. 4 receptor-induced responses: fading of the response and influence of development. Br J Pharmacol 147:140-157
17. Deschênes J, Dupere C, McNicoll N, L'Heureux N, Auger F, Fournier A, De Lean A (2005) Development of a selective peptide antagonist for the human natriuretic peptide receptor-B. Peptides 26:517-524
18. 1-adrenoceptors. Br J Pharmacol 153:710-720
19. 4 receptors. Br J Pharmacol 156:237-249
20. 1-adrenergic positive inotropic effect in human atrium. Cardiovasc Res 65:211-220
21. Hussain RI, Qvigstad E, Birkeland JA, Eikemo H, Glende A, Sjaastad I, Skomedal T, Osnes JB, Levy FO, Krobert KA (2009) Activation of muscarinic receptors elicits inotropic responses in ventricular muscle from rats with heart failure through myosin light chain phosphorylation. Br J Pharmacol 156:575-586
22. Jahnel U, Rupp J, Ertl R, Nawrath H (1992) Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn-Schmiedeberg's Arch Pharmacol 346:482-485
23. 4-like receptors. Naunyn-Schmiedeberg's Arch Pharmacol 342:619-622
24. 1 action on sinus pacemaker and adenylyl cyclase in kitten myocardium. Nature 251:515-517
25. Kaumann AJ, Levy FO (2006a) 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111:674-706
26. 4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium. Br J Pharmacol 147:128-130
27. Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ (1990) A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol 100:879-885
28. 1- adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 375:123-131
29. 4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur J Heart Fail 11:771-778
30. Läer S, Remmers F, Scholz H, Stein B, Müller FU, Neumann J (1998) Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. Br J Pharmacol 123:1182-1188
31. Levy FO, Qvigstad E, Krobert KA, Skomedal T, Osnes JB (2008) Effects of serotonin in failing cardiac ventricle: signalling mechanisms and potential therapeutic implications. Neuropharmacology 55:1066-1071
32. Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of β-adrenergic signaling in heart failure? Circ Res 93:896-906
33. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007
34. 2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol. doi: 10.1111/bph.12167
35. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67-75
36. Nikolaev VO, Bünemann M, Hein L, Hannawacker A, Lohse MJ (2004) Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem 279:37215-37218
37. 2-adrenergic receptor-mediated signaling. Circ Res 99:1084-1091
38. 2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327:1653-1657
39. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32-43
40. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K (1996) Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93:1963-1969
41. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468-1475
42. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355
43. Ponsioen B, Zhao J, Riedl J, Zwartkruis F, van der Krogt G, Zaccolo M, Moolenaar WH, Bos JL, Jalink K (2004) Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep 5:1176-1180
44. 4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc Res 65:869-878
45. Qvigstad E, Brattelid T, Sjaastad I, Molenaar P, Birkeland JA, Andressen KW, Krobert KA, Sejersted OM, Skomedal T, Osnes J-B, Kaumann AJ, Levy FO (2005b) Rationale for treatment of heart failure by blockade of ventricular serotonin receptors appearing in heart failure. Proceedings of the 25th European Section Meeting, International Society for Heart Research, Tromso, Norway, June 21-25, 2005. Medimond International Proceedings, Bologna, Italy, pp 7-12
46. 4 receptors induced in the acute failing heart. Circ Res 97:268-276
47. 1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 85:763-772
48. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, Lewinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Trial (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268-1277
49. Riise J, Nguyen CH, Qvigstad E, Sandnes DL, Osnes JB, Skomedal T, Levy FO, Krobert KA (2008) Prostanoid F receptors elicit an inotropic effect in rat left ventricle by enhancing myosin light chain phosphorylation. Cardiovasc Res 80:407-415
50. Robison GA, Butcher RW, Øye I, Morgan HE, Sutherland EW (1965) The effect of epinephrine on adenosine 3′,5′-phosphate levels in the isolated perfused rat heart. Mol Pharmacol 1:168-177
51. s-coupled receptors in adult rat ventricular myocytes. Circ Res 98:1081-1088
52. Rossmanith GH, Hoh JF, Turnbull L, Ludowyke RI (1997) Mechanism of action of endothelin in rat cardiac muscle: cross-bridge kinetics and myosin light chain phosphorylation. J Physiol 505(Pt 1):217-227
53. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293:1900-1905
54. 4 receptors in the pig. Naunyn-Schmiedeberg's Arch Pharmacol 346:629-636
55. Schoemaker RG, Du XY, Bax WA, Saxena PR (1992) 5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle. Naunyn-Schmiedeberg's Arch Pharmacol 346:486-489
56. Schoemaker RG, Du XY, Bax WA, Bos E, Saxena PR (1993) 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur J Pharmacol 230:103-105
57. Sutherland EW, Rall TW (1958) Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem 232:1077-1091
58. The Xamoterol in Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336:1-6
59. Vargas ML, Hernandez J, Kaumann AJ (2006) Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br J Pharmacol 147:158-163
60. 2+ current in rat ventricular myocytes. Br J Pharmacol 127:65-74
61. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036
62. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342:1441-1446
63. Warrier S, Belevych AE, Ruse M, Eckert RL, Zaccolo M, Pozzan T, Harvey RD (2005) Beta-adrenergic- and muscarinic receptor-induced changes in cAMP activity in adult cardiac myocytes detected with FRET-based biosensor. Am J Physiol Cell Physiol 289:C455-C461
64. 4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium. Naunyn-Schmiedeberg's Arch Pharmacol 385:565-577
65. 4 receptor activation in porcine left atrium. Naunyn-Schmiedeberg's Arch Pharmacol. doi: 10.1007/s00210-013-0855- 2
66. Yancy CW (2004) Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the Follow-Up Serial Infusion of Nesiritide (FUSION) Trial. Heart Fail Rev 9:209-216
67. Zaccolo M, Pozzan T (2002) Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295:1711-1715
68. Zaccolo M, De Giorgi F, Cho CY, Feng L, Knapp T, Negulescu PA, Taylor SS, Tsien RY, Pozzan T (2000) A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol 2:25-29